Primary Cell Culture Industry Overview

The global primary cell culture market size is expected to reach USD 11.59 billion by 2030, expanding at a CAGR of 13.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for personalized and precision therapies has fueled the need for more accurate and relevant in vitro models. Primary cell culture provides a closer representation of human biology and physiology compared to traditional cell lines, making it an indispensable tool for studying disease mechanisms, drug discovery, and therapeutic development. Researchers and pharmaceutical companies are increasingly recognizing the importance of primary cell culture for improving the success rates of drug candidates, reducing costly late-stage failures, and ultimately delivering more effective and targeted treatments to patients.

Moreover, the field of regenerative medicine aims to replace or repair damaged tissues and organs, and primary cell culture plays a vital role in developing and engineering functional tissues. Primary cells are used to create tissue constructs, organoids, and bioengineered implants that closely mimic the structure and function of native tissues. These advancements have significant implications for regenerative medicine therapies, including tissue transplantation, wound healing, and the treatment of degenerative diseases. For instance, in April 2023, Mount Sinai launched a new institute for regenerative medicine to foster novel discoveries and explore new therapies for life-threatening diseases. The growing interest in regenerative medicine and the potential to revolutionize healthcare have led to increased investment and research in primary cell culture, propelling the market’s growth.

Gather more insights about the market drivers, restrains and growth of the Primary Cell Culture Market

The COVID-19 pandemic has significantly impacted the primary cell culture industry. While the pandemic disrupted various industries, including healthcare and research, it highlighted the crucial role of primary cell culture in understanding viruses and developing treatments. Primary cells have been instrumental in studying the mechanisms of SARS-CoV-2 infection, testing antiviral therapies, and evaluating vaccine efficacy. The pandemic has accelerated the demand for primary cell culture products and services as researchers worldwide focused on COVID-19-related studies.

Furthermore, several developments undertaken by key market participants, and increasing industry-academia collaborations are driving the global market. For instance, in January 2023, Bio-Trac and ATCC collaborated to conduct a training workshop to offer an overview of the principles of primary cell culture, organoids and spheroids, and other related cell culture techniques.

 Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global stem cell therapy market size was estimated at USD 456.0 million in 2024 and is expected to grow at a CAGR of 25.23% from 2025 to 2030. 
  
  
• The US single-use bioprocessing market size was estimated at USD 9.34 billion in 2024 and is projected to grow at a CAGR of 15.04% from 2025 to 2030.

Primary Cell Culture Market Segmentation

Grand View Research has segmented the global primary cell culture market on the basis of product, separation method, cell type, application and region:

Primary Cell Culture Product Outlook (Revenue, USD Million, 2018 - 2030)

• Primary Cells
  • Fat
  • Blood
  • Nerve
  • Bone
  • Endothelial
  • Skin
  • Muscle
  • Stem
  • Others
• Reagents and Supplements
  • Attachment Solution
  • Buffers and salts
  • Freezing Media
  • Sera
  • Growth factors and cytokines
• Media
  • Fat cells media
  • Blood cells media
  • Nerve cells media
  • Bone cells media
  • Endothelial cells media
  • Skin cells media
  • Muscle cell media
  • Stem cells media
  • Others

Primary Cell Culture Separation Method Outlook (Revenue, USD Million, 2018 - 2030)

• Explant Method
• Enzymatic Degradation
  • Trypsin
  • Collagenase
  • Protease
  • Pronase
  • Dispase
  • Hyaluronidase
  • Neuraminidase
  • Elastase
  • DNase
  • Papain
  • Accutase
  • Others
• Mechanical Separation
• Others

Primary Cell Culture Cell Type Outlook (Revenue, USD Million, 2018 - 2030)

• Animal Cells
• Human Cells

Primary Cell Culture Application Outlook (Revenue, USD Million, 2018 - 2030)

• Cell Gene Therapy Development
• Vaccine Production
• Model System
• Virology
• Prenatal Diagnosis
• Others

Primary Cell Culture Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait 

Key Companies profiled:

• Thermo Fisher Scientific, Inc.
• Lonza
• Merck
• Corning Incorporated
• Danaher
• PromoCell GmbH
• ATCC
• FUJIFILM Irvine Scientific, Inc.
• Mattek
• Axol Bioscience Ltd.

Key Primary Cell Culture Company Insights

Some of the key players operating in the market include Thermo Fisher Scientific, Inc., Merck, and Danaher.

• Thermo Fisher Scientific, Inc. provides an extensive array of primary cell culture products, encompassing diverse primary cultures, established cell lines, and a comprehensive selection of reagents, media, sera, and growth factors essential for conducting cell culture experiments.
• Merck delivers a comprehensive solution tailored for the selective cultivation of malignant cells. Additionally, the company offers a portfolio comprising fully characterized, ready-to-use Peripheral Blood Mononuclear Cells (PBMCs) in both standard and disease states, along with a diverse range of immune cell subsets.
• ATCC and Mattek are some of the emerging market players.
• ATCC offers a range of primary cell culture products, including cell types such as fibroblasts, endothelial cells, epithelial cells, and various stem cell types.

Recent Developments

• In February 2023, Thermo Fisher Scientific, Inc. announced a collaboration with Celltrio, a manufacturing company, to enable a fully automated cell culture system for their customers.
• In October 2023, Kuraray Co., Ltd. introduced PVA hydrogel microcarriers tailored for cell cultures in regenerative medicine. The product is set to be launched in Japan and globally, with the initial release slated for January 2024, starting in the U.S.
• In February 2022, Cellula Revolution secured USD 2.2 million in funding to speed up the launch of their Continuous Cell Culture Technology

Order a free sample PDF of the Primary Cell Culture Market Intelligence Study, published by Grand View Research.